Experienced in Hairy Cell Leukemia (HCL)

Dr. Diwakar Davar

Hematology | Oncology
UPMC
University Of Pittsburgh Physicians
300 Halket St, 
Pittsburgh, PA 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Hairy Cell Leukemia (HCL)
UPMC
University Of Pittsburgh Physicians
300 Halket St, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Diwakar Davar is a Hematologist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Davar is rated as an Experienced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Metastatic Uveal Melanoma, Uveal Melanoma, and Gamma Knife Radiosurgery.

His clinical research consists of co-authoring 92 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 4 clinical trials in the study of Hairy Cell Leukemia (HCL).

Specialties
Hematology
Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
Magee Womens Hospital Of Upmc Health System
Upmc Horizon
Upmc Presbyterian Shadyside
Upmc Altoona
Upmc Passavant
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

UNIVERSITY OF PITTSBURGH PHYSICIANS
300 Halket St, Pittsburgh, PA 15213
Call: 412-623-2458
Other Locations
UNIVERSITY OF PITTSBURGH PHYSICIANS
5230 Centre Ave, Suite 509, Pittsburgh, PA 15232
Call: 412-623-2458
UNIVERSITY OF PITTSBURGH PHYSICIANS
200 Lothrop St, Muh 4 East, Pittsburgh, PA 15213
Call: 412-383-1370

Additional Areas of Focus

Dr. Davar has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
Enrollment Status: Recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: May 29, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Phase: Phase 1
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination With Dual BRAF/MEK Inhibition in Patients With BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor Therapy
Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination With Dual BRAF/MEK Inhibition in Patients With BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor Therapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Tazemetostat Hydrobromide, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 1/Phase 2
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Biological, Drug
Study Drugs: Olaparib, Ramucirumab
Study Phase: Phase 1/Phase 2
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Biological
Study Drugs: Bevacizumab, Ipilimumab
Study Phase: Phase 2
Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination With CMP-001 in Patients With Operable Melanoma: Efficacy and Biomarker Study
Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination With CMP-001 in Patients With Operable Melanoma: Efficacy and Biomarker Study
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Pembrolizumab, VLP-Encapsulated TLR9 Agonist CMP-001
Study Phase: Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: October 27, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
PHASE II NEOADJUVANT STUDY OF PD-1 INHIBITOR DOSTARLIMAB (TSR-042) VS. COMBINATION OF TIM-3 INHIBITOR COBOLIMAB (TSR-022) AND PD-1 INHIBITOR DOSTARLIMAB (TSR-042) IN RESECTABLE STAGE III OR OLIGOMETASTATIC STAGE IV MELANOMA (NEO-MEL-T)
PHASE II NEOADJUVANT STUDY OF PD-1 INHIBITOR DOSTARLIMAB (TSR-042) VS. COMBINATION OF TIM-3 INHIBITOR COBOLIMAB (TSR-022) AND PD-1 INHIBITOR DOSTARLIMAB (TSR-042) IN RESECTABLE STAGE III OR OLIGOMETASTATIC STAGE IV MELANOMA (NEO-MEL-T)
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Dostarlimab (TSR-042) (Singly), Dostarlimab (TSR-042) and TSR-022 (Combination)
Study Phase: Phase 2
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Biological, Drug
Study Drugs: Ipilimumab, Nivolumab, Prednisone, Tacrolimus
Study Phase: Phase 1
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Phase II Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
Phase II Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: May 29, 2025
Intervention Type: Drug
Study Drug: Pembrolizumab Injection
Study Phase: Phase 2
Phase IIA Basket Study of Pixatimod (PG545) in Combination With Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and Pixatimod (PG545) in Combination With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
Phase IIA Basket Study of Pixatimod (PG545) in Combination With Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and Pixatimod (PG545) in Combination With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
Enrollment Status: Completed
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drugs: Pixatimod, Nivolumab, Cyclophosphamide
Study Phase: Phase 2
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drugs: SEA-TGT, Pembrolizumab
Study Phase: Phase 1
Randomized Neoadjuvant Pilot Phase II Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab in Stage IIIB/C/D Melanoma Patients with an Integrated Imaging Biomarker
Randomized Neoadjuvant Pilot Phase II Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab in Stage IIIB/C/D Melanoma Patients with an Integrated Imaging Biomarker
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: CMP-001, Nivolumab
Study Phase: Phase 2
A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors
A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: March 23, 2023
Intervention Type: Drug
Study Drug: SGN-CD228A
Study Phase: Phase 1
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 18 Less Clinical Trials

92 Total Publications

Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma.
Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
View All 92 Publications
Similar Doctors
Advanced in Hairy Cell Leukemia (HCL)
Dr. Dhaval R. Mehta
Oncology | Hematology
Advanced in Hairy Cell Leukemia (HCL)
Dr. Dhaval R. Mehta
Oncology | Hematology

Oncology Hematology Association Inc

5115 Centre Ave, Fl 3, 
Pittsburgh, PA 
 (1.5 miles away)
412-235-1020
Languages Spoken:
English
See accepted insurances

Dhaval Mehta is an Oncologist and a Hematologist in Pittsburgh, Pennsylvania. Dr. Mehta is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Polycythemia Vera, Paget Disease of the Breast, Familial Pancreatic Cancer, and Neuroendocrine Tumor.

Antoine E. Chahine
Advanced in Hairy Cell Leukemia (HCL)
Dr. Antoine E. Chahine
Hematology | Oncology | Internal Medicine
Advanced in Hairy Cell Leukemia (HCL)
Dr. Antoine E. Chahine
Hematology | Oncology | Internal Medicine

Blood And Cancer Center, Inc.

3695A Boardman Canfield Road, 
Canfield, OH 
 (58.0 miles away)
330-533-3040
Languages Spoken:
English
See accepted insurances

Antoine Chahine is a Hematologist and an Internal Medicine provider in Canfield, Ohio. Dr. Chahine is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Familial Colorectal Cancer, Paget Disease of the Breast, Colorectal Cancer, and Inflammatory Breast Cancer.

Advanced in Hairy Cell Leukemia (HCL)
Dr. Mounzer Agha
Hematology
Advanced in Hairy Cell Leukemia (HCL)
Dr. Mounzer Agha
Hematology

Oncology Hematology Association Inc

5115 Centre Ave, Fl 3, 
Pittsburgh, PA 
 (1.5 miles away)
412-235-1020
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mounzer Agha is a Hematologist in Pittsburgh, Pennsylvania. Dr. Agha is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

VIEW MORE HAIRY CELL LEUKEMIA (HCL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Davar's expertise for a condition
ConditionClose
  • Elite
  • Melanoma
    Dr. Davar is
    Elite
    . Learn about Melanoma.
    See more Melanoma experts
  • Distinguished
  • Merkel Cell Carcinoma
    Dr. Davar is
    Distinguished
    . Learn about Merkel Cell Carcinoma.
    See more Merkel Cell Carcinoma experts
  • Metastatic Uveal Melanoma
    Dr. Davar is
    Distinguished
    . Learn about Metastatic Uveal Melanoma.
    See more Metastatic Uveal Melanoma experts
  • Advanced
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
    Dr. Davar is
    Advanced
    . Learn about Head and Neck Squamous Cell Carcinoma (HNSCC).
    See more Head and Neck Squamous Cell Carcinoma (HNSCC) experts
  • Lung Cancer
    Dr. Davar is
    Advanced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Melanoma of the Eye
    Dr. Davar is
    Advanced
    . Learn about Melanoma of the Eye.
    See more Melanoma of the Eye experts
  • Neuroendocrine Tumor
    Dr. Davar is
    Advanced
    . Learn about Neuroendocrine Tumor.
    See more Neuroendocrine Tumor experts
  • Non-Small Cell Lung Cancer (NSCLC)
    Dr. Davar is
    Advanced
    . Learn about Non-Small Cell Lung Cancer (NSCLC).
    See more Non-Small Cell Lung Cancer (NSCLC) experts
  • Pleuropulmonary Blastoma
    Dr. Davar is
    Advanced
    . Learn about Pleuropulmonary Blastoma.
    See more Pleuropulmonary Blastoma experts
View All 10 Advanced Conditions
  • Experienced
  • Acinic Cell Carcinoma of Salivary Glands
    Dr. Davar is
    Experienced
    . Learn about Acinic Cell Carcinoma of Salivary Glands.
    See more Acinic Cell Carcinoma of Salivary Glands experts
  • Adenoid Cystic Carcinoma
    Dr. Davar is
    Experienced
    . Learn about Adenoid Cystic Carcinoma.
    See more Adenoid Cystic Carcinoma experts
  • Adult Soft Tissue Sarcoma
    Dr. Davar is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Davar is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Astrocytoma
    Dr. Davar is
    Experienced
    . Learn about Astrocytoma.
    See more Astrocytoma experts
  • Atypical Teratoid Rhabdoid Tumor (ATRT)
    Dr. Davar is
    Experienced
    . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
    See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
View All 57 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.